Filing Flows › Neuroone Medical Technologies (NMTC) › Q1 FY26
Neuroone Medical Technologies (NMTC) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 17, 2026
Neuroone Medical Technologies (NMTC) reported revenue of $2.9M for the first quarter fiscal 2026 (Q1 FY26), -12% from a year earlier and +6% from the quarter before. Operating margin was -59.0%, net loss $1.4M (49.7% of revenue).
Neuroone Medical Technologies, Q1 FY26: revenue $2.9M (-12% year over year), operating margin -59.0%, net loss $1.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | +6% | -12% |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$3.1M | — | — |
What changed
Revenue was $2.9M in Q1 FY26, down 12% year over year and up 6% from the previous quarter.
Gross margin was 54.2%, down 4.7 points from a year earlier. Operating costs exceeded revenue by $1.7M, an operating margin of -59.0%. Operating expenses grew 1419% against a revenue fall of 12%. The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $1.6M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $66K of depreciation and amortization and $359K of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $41K exceeded it, leaving free cash flow of −$3.2M.
Questions
What was Neuroone Medical Technologies' revenue in the first quarter fiscal 2026?
Neuroone Medical Technologies (NMTC) reported revenue of $2.9M for the first quarter fiscal 2026 (Q1 FY26), -12% from a year earlier and +6% from the quarter before.
Was Neuroone Medical Technologies profitable in the first quarter fiscal 2026?
Operating loss was $1.7M (-59.0% of revenue) and net loss $1.4M.